- Home
- AMAL vs CVAC Comparison
AMAL vs CVAC Comparison
Compare AMAL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | CVAC |
|---|---|---|
| Founded | 1923 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMAL | CVAC |
|---|---|---|
| Price | $33.06 | $4.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $33.50 | $6.83 |
| AVG Volume (30 Days) | 170.2K | ★ 2.0M |
| Earning Date | 01-22-2026 | 11-24-2025 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 3.32 | 0.94 |
| Revenue | ★ $305,836,000.00 | $83,000,117.00 |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $8.37 | $23.40 |
| P/E Ratio | $9.89 | ★ $4.40 |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $25.03 | $2.48 |
| 52 Week High | $37.26 | $5.72 |
Technical Indicators
Market Signals| Indicator | AMAL | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 30.76 |
| Support Level | $32.68 | $4.00 |
| Resistance Level | $33.75 | $5.20 |
| Average True Range (ATR) | 0.65 | 0.16 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 80.37 | 22.51 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.